C aveolae are small (50-100 nm in size) plasma invaginations with a cup-like shape 1 and a composition of cholesterol and other lipids that classify them as lipid rafts. These rafts are enriched in a large number of protein complexes involved in signaling and vesicular trafficking. 2 The physical orientation and localization of ion channels 14 and signaling molecules, for example, β 2 -adrenoreceptor, in caveolae are of functional significance. 2, [15] [16] [17] Caveolin-3 is associated with the α-subunit of the Nav1.5 ion channel conducting the depolarizing I Na current, 9 and interference with this association has been suggested as the mechanism of CAV3-associated LQTS or sudden infant death syndrome. 9, 11 Another tentative mechanism may be the altered interaction between caveolin-3 and the α-subunit of the Kv11.1 (encoded by KCNH2) conducting the I Kr current also involved in LQTS. An association with Kv11.1 has been documented for both caveolin-1, in stably transfected human embryonic kidney 293 cells (human ether-a-go-go-related gene [hERG]:HEK), 18, 19 and caveolin-3, in neonatal rat ventricular myocytes. 19 These associations result in the sensitivity of Kv11.1 to extracellular K + . 19 We examined the occurrence of CAV3 mutations in 167 LQTS probands by sequencing the coding regions of the gene. Furthermore, we describe a family with mutations in CAV3 and a novel KCNH2 mutation, where the functional characterization indicates that the KCNH2 mutation is disease causing. Finally, we use our own findings, together with published reports on CAV3 mutations, to question whether described mutations in this gene are in fact LQTS causative.
Materials and Methods

Patients
Unrelated probands, referred from specialist cardiology centers in Denmark and the United Kingdom to Statens Serum Institut for genetic investigation of LQTS (n=167; 61% women), were included in the study. The probands had been screened by capillary-electrophoresis single-strand conformation polymorphism for mutations in KCNQ1, KCNH2, KCNE1, KCNE2, and SCN5A, as described elsewhere. [20] [21] [22] Fifty-eight (35%) patients had been found to carry a probably damaging variant in any one of these genes. A control panel comprising 189 Danish blood donors was used to assess population frequencies of the identified variants. Furthermore, data from the 1000 genomes project 23 
CAV3 Screening
DNA was extracted from frozen EDTA-blood using a Qiagen kit (Qiagen; QmbH, Hilden, Germany). Screening for mutations in CAV3 was performed by direct sequencing using primers that flanked the coding region (primer sequences and polymerase chain reaction conditions are available on request). Polymerase chain reaction products were quantified on agarose gel electrophoresis, purified using ExoSap (Affymetrix, Santa Clara, CA), and sequenced using the Big Dye dideoxy terminator cycle sequencing kit (Applied Biosystems, Foster City, CA) and the 3100 ABI-PRISM automated sequencer (Applied Biosystems). Sequence analysis was performed using the Sequencher 4.8 software (Gene Codes Corporation, Ann Arbor, MI).
Definition of Disease Causation or Association
Genetic variants were considered probably damaging if (1) the nucleotide variation was deduced to result in a missense mutation, frameshift, and abnormal splicing; (2) relevant, the variation affected a conserved amino acid; (3) the variation cosegregated with the disease in affected family members; and (4) the variation was not identified among 189 Danish blood donors. In the absence of available family members for cosegregation studies, disease association was presumed if criteria 1, 2, and 4 were fulfilled. If the mutation had been associated with disease previously-in accordance with the criteria mentioned here and relevant functional studies-disease causation was presumed when just criteria 1 and 4 were met.
Cell Cultures, Transfections, and DNA Constructs
Human embryonic kidney 293 cells were cultured in Eagle minimal essential medium (MEM) with Glutamax supplemented with 10% fetal bovine serum and penicillin/streptomycin (100 U/mL; 100 mg/mL) at 37°C and 5% CO 2 . For Western blot and immunoprecipitation analysis, cells were transfected transiently with Lipofectamine 2000 (Invitrogen, Carlsbad, CA) according to manufacturer instruction. Cells were plated to be 90% confluent at transfection day and transfected with 4 μg of total DNA in 6-well plates for Western blot. The FEDVIAEP caveolin signature domain is indicated within the N terminal. Previously reported mutations have been indicated as green stripes along with the diseases reported to be associated with them. Caveolin-3:p.T78M is represented by a red stripe. Nonsynonymous variants represented in the exome variant server are indicated in black, and the frequencies of these variants are shown for European Americans (EA) and African Americans (AA). DCM indicates dilated cardiomyopathy; DM, distal myopathy; H-CK, hyperCKemia; HCM, hypertrophic cardiomyopathy; LGMD, limb-girdle muscular dystrophy; LQTS, long-QT syndrome; RMD, rippling muscular dystrophy; and SIDS, sudden infant death syndrome.
For electrophysiology recordings, cells were cotransfected in T25 flasks with 2 μg of total amount of DNA together with 0.2 μg of green fluorescent protein for detection of successfully transfected cells.
The human KCNH2 and the CAV3 cDNA constructs were purchased from OriGene Technologies, Inc, (Rockville, MD). The caveolin-3:p.T78M and the Kv11.1:p.I400N mutants were obtained by inserting point mutations in the CAV3 and KCNH2 constructs, respectively. The constructs were confirmed by direct sequencing, and the proteins were verified with Western blot analysis.
Coimmunoprecipitation
Protein samples were prepared 48 hours after cell transfection by 30-minute solubilization in ice-cold buffer containing Triton 1%, NP40 1%, 50 mmol/L Tris-HCl pH 7.4, 150 mmol/L NaCl, 2 mmol/L EDTA, 10% glycerol, 1 mmol/L PMSF, 1 mmol/L Na 3 VO 4 , 5 mmol/L NaF supplemented with fresh protease inhibitor cocktail EDTA free (La Roche, Indianapolis, IN). A total of 400 μg of protein extract was precleared by incubation with 60 μL of 1:1 slurry of protein G-Agarose beads for 2 hours at 4°C. The clarified fractions were then incubated overnight at 4°C with goat polyclonal anti-hERG antibody (sc-15968; Santa Cruz Biotechnology Inc, Santa Cruz, CA) or polyclonal IgG isolated from normal goat serum for negative control. Immune complexes were precipitated finally with protein G-Agarose for 2 hours at 4°C, collected by centrifugation, washed 5× in washing buffer (Triton 0.1%, NP40 0.1%, 50 mmol/L Tris-HCl pH 7.4, 150 mmol/L NaCl, 2 mmol/L EDTA, and 10% glycerol), and disrupted by incubation in denaturing Laemmli sample buffer. The complexes were separated on 4% to 15% gel and transferred to polyvinylidene difluoride membrane. After blocking, membranes were probed with anti-hERG (1:1000; sc-15968; Santa Cruz) or anti-Cav3 antibody (1:500; sc-5310; Santa Cruz), and the appropriate secondary antibody was conjugated with horseradish peroxidase. A total of 20 μg of each protein extract was also loaded on the gel to check the efficiency of transfection. Signals were detected using an ECL west-pico detection kit (Thermo Scientific, Rockford, IL).
Cellular Electrophysiology
Two days after transfection, cells were harvested and laid on 0.5-cm coverslips for 1 hour. Electrophysiology recordings were performed in the whole-cell patch-clamp configuration at room temperature using an EPC-9 patch-clamp amplifier (HEKA Elektronik, Lambrecht/Pfalz, Germany). Data acquisition was performed with the Pulse software (HEKA Elektronik). Resistances obtained ranged from 1.5 to 2.5 MΩ when pipettes were filled with a solution containing 5.17 mmol/L CaCl 2 , 1.42 mmol/L MgCl 2 , 31/10 mmol/L KOH/EGTA, 110 mmol/L KCl, 4 mmol/L K 2 ATP, and 10 mmol/L Hepes (pH 7.4 adjusted with KOH). The cells were in superfusion with solution containing: 140 mmol/L NaCl, 4 mmol/L KCl, 2 mmol/L CaCl 2 , 1 mmol/L MgCl 2 , and 10 mmol/L Hepes (pH 7.4 adjusted with NaOH). The series resistances recorded in the whole-cell configuration ranged from 1.5 to 8 mΩ. Voltage protocols used for channel activation recordings were depolarizing steps ranging from −80 to +60 mV preceded by a short sweep at −100 mV to ensure that all channels had recovered from inactivation. A step protocol ranging between −120 and −40 mV for 1 second was used for channel deactivation. For all protocols, the holding potential was 80 mV. Exact protocols are indicated in the corresponding figures.
Data Analysis
Data analysis was performed using Igor Pro Software (WaveMetrics, Lake Oswego, OR). No leak subtraction was used during current recordings, and current densities were normalized to cell capacitance. Deactivation kinetic analysis was performed by calculating the time constants of double exponential functions fitted on the currents measured. Data were fit with the Boltzmann function. The significance of differences between the recordings was calculated using the t test.
Analysis of Trafficking
Forty-eight hours after transfection, cells were lysed in Triton 1%, 50 mmol/L Tris-HCl pH 7.4, 150 mmol/L NaCl, 2 mmol/L EDTA, 10% glycerol, 1 mmol/L PMSF, 1 mmol/L Na 3 VO 4 , and 5 mmol/L NaF buffer supplemented with fresh protease inhibitor cocktail EDTA free (La Roche). Lysates were cleared at 12 000 rpm for 15 minutes, and protein concentration was determined by Bradford assay. Equal amounts of protein (20 μg) were heated for 10 minutes at 60°C and subjected to SDS-PAGE on a 7.5% gel followed by transfer on polyvinylidene difluoride membranes. After blocking, membranes were incubated with primary antibodies against hERG C-terminal (1:1000; sc-15968; Santa Cruz) or rabbit antiactin (Sigma) and appropriate secondary horseradish peroxidase-conjugated antibody.
Bioinformatics
Caveolin-3 reference sequences NM_001234.3 and NP_001225.1 were used for variant annotation. All variants were checked with Mutalyser Name Checker, 24 and SNPCheck v2.1 (https://ngrl.manchester.ac.uk/SNPCheckV2/snpcheck.htm) was used to assess primer sequences for potential SNPs, as well as to collect known SNP data for the amplified regions. National Center for Biotechnology Information SNP database and the Exome Variant Server (http:// evs.gs.washington.edu/EVS/) were used to collect frequency data on known SNPs. Clustal W2 (http://www.ebi.ac.uk/Tools/msa/ clustalw2/) 25 26 was used to assess the effect the identified variants might have on splicing. Deviation from Hardy-Weinberg Equilibrium was tested using GenePop (http://genepop.curtin.edu.au/genepop_op1.html). 27, 28 Electrocardiography ECGs of selected family members were recorded in the supine position at rest on digital ECG recorders (GE Medical Systems, Milwaukee, WI), with a standard 12-lead system and 10-second duration at a sampling rate of 500 Hz. Data from a control group were acquired from the GE-Marquette research database of healthy volunteers. 29 QT intervals were preferentially measured manually in lead V5. If T-waves were immeasurable, lead II or lead V2 were chosen. T-wave morphology features, including flatness, asymmetry, and notches, were measured as morphology combination score (MCS) as described by Graff et al 30 to quantitate differences in T-wave morphology between carriers of caveolin-3:p.T78M, Kv11.1:p.I400N, double heterozygote carriers, and healthy subjects. A mean (SD) MCS value of 1.80 (0.60) has been reported in 30 patients with LQTS2 as opposed to 0.71 (0.24) in 917 healthy controls. An MCS value of 1.1 defines the cutoff between normal controls and patient with significant I Kr reduction because of 160 mg of sotalol or an LQTS2 phenotype. 30
Ethics
All patients had given informed consent of genetic screening according to the law and clinical practices of the respective countries.
Results
One LQTS proband (0.6%) was identified as a heterozygous carrier of the missense mutation CAV3 c.233C>T: p.T78M that has been previously associated with LQTS, 9 as well as sudden infant death syndrome. 11 This threonine residue is highly conserved in mammals.
A further 15 non-disease-causing genetic variants, 3 in the 5-prime untranslated region part of the gene, 5 from the intronic regions around the intron/exon boundaries, and 7 synonymous variants from the coding region, were identified as detailed in Table 1 . Ten of the variants described here, including caveolin-3:p.T78M, had been registered in the SNP database. Some of the variants had a very low prevalence. The frequent genotypes were in Hardy-Weinberg Equilibrium, although the frequency of the rare variants was too low for a reliable Hardy-Weinberg Equilibrium estimation.
Of the variants not previously described in an SNP database, 2 were 5-prime untranslated region SNPs (c.-34C>T and c.-15C>A), 2 were intronic variants (c.114+32A>G and c.115-32delT), and 2 were synonymous variants (c.12A>G:p.E4= and c.240G>A:p. L80=). All these variants were extremely rare and occurred only in the LQTS cohort. There was no appreciable effect on splicing by these variants as assessed by in silico analysis.
The caveolin-3:p.T78M carrying proband was also a heterozygous carrier of the Kv11.1:p.I400N mutation. The pedigree and clinical synopsis are shown in Figure 2 . Three family members (II-2, II-4, and III-7) carry the caveolin-3:p.T78M mutation in isolation. All 3 reported syncopal episodes: II-2, an 80-year-old woman (8 years after diagnosis at 72 years), had 2 syncopes and a severely prolonged PQ interval of 0.52 ms, AV block was assumed and a DDD pacemaker was implanted, and the patient has been symptom free since; II-4 had a syncopal episode once during painful delivery; and III-7 fainted once during an accident where her hand was lacerated in a machine. The 3 isolated caveolin-3:p.T78M carriers (II-2, II-4, and III-7) had heart rates of 56, 75, and 75 bpm, respectively. All Kv11.1:p.I400N carriers had a Schwartz score ≥4 except IV-3 with a score of 3. Family members only carrying the caveolin-3:p.T78M mutation had a Schwartz score of 2, on the basis of normal QTc interval, nonexertional syncope, and positive family history. Twelve-lead ECG traces of the caveolin-3:p.T78M carriers are shown in Figure I Table 2 , indistinguishable from that of healthy subjects. 30 Furthermore, no SCN5A morphology with prolonged isoelectric ST segments and narrow T-waves was apparent in these cases ( Figure I in the online-only Data Supplement).
Western blot analysis indicated that cells expressing wild-type (WT) Kv11.1 channel proteins exhibited both a 135-kDa and a mature 155-kDa protein band, whereas cells expressing the Kv11.1:p.I400N substitution exhibited only the 135-kDa protein band ( Figure 3A) . Quantification of the amount of mature channel at the plasma membrane confirmed that, compared with WT Kv11.1, less Kv11.1:p. I400N channel was present at the plasma membrane (n=8; P=0.001; Figure 3B ). Electrophysiological characterization of the Kv11.1:p.I400N mutant is shown in Figure 4 . The Kv11.1:p.I400N mutant displayed considerably lower peak currents. The mean currents measured at the end of a 2-second depolarizing pulse at 0 mV were 0.030±0.007 pA/pF for WT compared with 0.014±0.003 pA/pF for Kv11.1:p.I400N (P=0.046). Mean tail currents recorded at 60 mV were 0.114±0.022 pA/pF for WT compared with 0.023±0.006 pA/pF for Kv11.1:p.I400N (P<0.0001). Normalized tail currents for progressive increase of voltage were lower in Kv11.1:p.I400N channels when compared with WT ( Figure 4D) . No difference was observed between WT and Kv11.1:p.I400N in the deactivation rates. Interaction between Kv11.1 and caveolin-3 was confirmed by coimmunoprecipitation analysis ( Figure 5A ). Furthermore, the interaction between caveolin-3 and Kv11.1 is not compromised by either caveolin-3:p.T78M or Kv11.1:p.I400N mutations ( Figure 5B ).
Discussion
Clinical Genetics
We have identified 1 CAV3 variant (c.233C>T; p.T78M) in 167 LQTS cases. This variant falls within the central hydrophobic transmembrane domain (amino acids 75-106) of caveolin-3 and has previously been reported to be disease causing. Of the 16 CAV3 variants identified in the LQTS population, 10 of them occurred at a frequency of <1% in this population. Three of these rare variants were identified in the Danish control group, and 2 occurred with a frequency of <1% in this group. Only 1 of these, caveolin-3:p.T78M, was also identified in the 1000 genomes cohort at a frequency of 0.1%. The significance of these rare variants is unclear. In silico analyses of these variants suggest that they all have the possibility of disrupting exon splicing silencer or enhancer sites and thereby affecting splicing. However, without further experimental evidence, it is difficult to ascribe pathophysiological significance to these variants. Furthermore, caveolin-3:p.T78M carriers do not manifest an SCN5A ST-T wave pattern. Although all the 3 single caveolin-3:p.T78M carriers had experienced syncope, these could be attributed to AV block or a neurocardiogenic mechanism.
CAV3 Mutations and Disease Association
The caveolin-3:p.T78M mutation was reported originally in 3 unrelated patients with LQTS, 1 of whom also carried Kv11.1:p.A913V. On the basis of clinical presentation of 2 of the patients, the authors concluded that caveolin-3:p.T78M may modulate the I Na and may reduce the sinus rate producing clinical features characteristic of LQT3. 9 However, of the 3 patients carrying only the caveolin-3:p.T78M mutant, 2-a 14-year-old girl and an 8-year-old boy-had normal QTc intervals of 405 and 433 ms, respectively. The last, a 40-year-old man, had a QTc interval of 456 ms that could be considered borderline prolonged 9 ; however, as reported by Drew et al, 31 QTc intervals of 470 ms in postpubertal men and 480 ms in postpubertal women are considered the upper limits of normal. Data aggregated from Vatta et al 9 and the present study (Table 2 ) indicate a paucity of evidence supporting CAV3 as an LQTS-causing gene. A subsequent study by Cronk et al 11 identified caveolin-3:p.T78M in a sudden infant death syndrome case. The authors concluded that, as caveolin-3 colocalizes with β 2 -adrenoreceptors in ventricular and sinoatrial myocytes, [32] [33] [34] disruption of caveolae by mutations in caveolin-3 might affect the β-adrenergic responsiveness and the excitation-contraction coupling of cardiac myocytes. The caveolin-3 p.T78M mutation has also been found in a subject with idiopathic hyperCKemia, although in this case immunohistochemical analysis of caveolin-3 in a muscle biopsy was normal. 35 Traverso et al 3 described a case where a homozygous caveolin-3:p.T78M carrier developed severe limb-girdle muscular dystrophy with dilated cardiomyopathy, whereas a heterozygous offspring was asymptomatic, suggesting an autosomal recessive mode of inheritance for this trait. In vitro studies showed that caveolin-3:p.T78M impairs the ability of the caveolin-3 hydrophobic domain to assemble caveolin-3 homo-oligomers units for the formation of caveolae in muscle cells. [36] [37] [38] Furthermore, the first case of a heterozygous caveolin-3:p.T78M mutation associated with rippling muscle disease and proximal weakness was reported by Ricci et al 39 in which immunohistochemical analysis of skeletal muscle confirmed reduced caveolin-3 immunolabeling. The patient was also affected by mild facioscapulohumeral muscular dystrophy that was explained by a D4Z4 partial deletion. However, weakness of the pelvic girdle muscles, a complaint not usually present in facioscapulohumeral muscular dystrophy, 40 and the rippling phenomenon, a specific sign of caveolinopathy, has never been associated with D4Z4-reduced allele expression. Subsequently, Spadafora et al 41 questioned the association of caveolin-3:p. T78M with disease. They presented a case in which caveolin-3:p.T78M was found in a woman presumed to suffer from distal myopathy. A final diagnosis of mild frontotemporal dementia was determined, and as the proband's father was suspected to have died with parkinsonism, it was surprising that the proband had inherited the caveolin-3:p.T78M variant from her clinically nonaffected mother. The authors also point out that caveolin-3:p.T78M has a frequency of 1.5% in Italy and hypothesize that either the association of this variant with disease is incidental or specific population factors are required to modify the effect of this variant. 41 Collectively, these data do not support the hypothesis that the caveolin-3:p.T78M mutation is pathogenic in the heterozygous state. It may be that caveolin-3:p.T78M exerts an effect in association with other genetic factors. Genotypephenotype correlation studies in caveolinopathies suggest that genetic modifiers may contribute to the phenotype. 3, 13, 42, 43 As seen in Table 2 , the caveolin-3:p.T78M is not independently associated with a prolonged QT or with previous syncope, despite its previously described electrophysiology effect (a 4-fold increase in the late I Na ). 11 Several cardiac ion channels have been reported to be localized within caveolae: HCN4, Nav1.5, Kv1.5, Cav1.2, and Kv11.1. 44, 45 The complex regulation of these ion channels within macromolecular complexes in caveolae 19, 45 suggests that the effect CAV3 mutations might exert on individual channels would produce a cumulative effect on the currents that make up the action potential. The ion channels listed above play critical roles in different phases of the cardiac action potential. Therefore, it is meaningless to assess the effects that CAV3 mutations have on a single ion channel without being able to assess the effect on the action potential as a whole. The findings that 2 of the caveolin-3:p.T78M carriers had reported a previous syncope and 1 had a slight 1° AV block could, however, indicate that CAV3 mutations may increase the propensity for numerous types of arrhythmia depending on the involved interacting ion channel.
An interesting possibility is that CAV3 mutations affect the I Kr current predominantly under hypokalemic conditions, where CAV3 is known to play a role in the availability of Kv11.1 at the cell membrane. 19 This would be in accordance with the known sensitivity of the I Kr current to external hypo-and hyperkalemia. 46 This interdependence between hypokalemia and CAV3 function may explain the highly variable phenotypic expression of CAV3 mutations.
However, in the absence of an LQTS phenotype in any of the isolated caveolin-3:p/T78M carriers, despite that this mutation has the signature in vitro electrophysiological effect of LQTS9, it would seem reasonable to consider LQTS9 a provisional entity until an association between the clinical LQTS phenotype and CAV3 mutations has been established. 
Cellular Electrophysiology
Cellular protein synthesis is a tightly controlled process where incorrectly processed proteins may be retained until they are correctly processed, retrogradely transported to an earlier compartment, and targeted for degradation. The processing of Kv11.1 channel proteins includes 2 glycosylation steps. Immature Kv11.1 proteins undergo N-linked core glycosylation in the endoplasmic reticulum (135 kDa), whereas complex glycosylation occurs in the Golgi apparatus (155 kDa); this mature form of Kv11.1 is inserted into the cell membrane. 47, 48 Using this defective glycosylation as a representation of defective trafficking, Anderson et al 49 reported that most Kv11.1 mutations were trafficking deficient. Our results suggest that Kv11.1:p. I400N results in a trafficking deficiency of the Kv11.1 channel subunit.
Electrophysiological assessment of the Kv11.1:p.I400N mutation indicated that there is no effect on the gating of the mutant and confirmed the Western blot analysis that the mutation results in a reduced number of total functional channels present on the membrane.
Limitations
This study may be limited with respect to the method used for mutation screening. Direct sequencing of the coding regions of CAV3 cannot identify large deletions or duplications that would be more suitably identified by MLPA; it is also limited in identifying intronic variants as only the intronic regions close to the intron/exon boundaries are interrogated by this method. Consequently, we cannot comment on the role of CAV3 structural rearrangements or the genetic variation CAV3 regulatory regions may play in LQTS.
Conclusions
CAV3 mutations are present in LQTS, but they are rare and may not have any clinical consequence, despite an electrophysiology in vitro phenotype. There is no evidence indicating that the caveolin-3:p.T78M mutation is disease causing. As caveolin-3:p.T78M has been shown to generate the signature electrophysiological effect of LQTS9, and we have demonstrated that this effect is not associated with LQTS, it is most reasonable to consider LQTS9 a provisional entity until an association with clinical LQTS can be established. In this study, all symptomatic patients are heterozygote carriers of the Kv11.1:p.I400N mutation, which has shown to be associated with trafficking deficiency and reduced peak current. This functional effect is the clinical pathogenic mechanism in LQTS2. 50, 51 CAV3 analysis need not be performed routinely in the genetic workup of patients with LQTS, and the findings of rare variants in CAV3 should be handled with caution, particularly with respect to their clinical significance.
